Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03627208
Other study ID # 999918131
Secondary ID 18-C-N131
Status Completed
Phase
First received
Last updated
Start date August 2, 2018
Est. completion date April 14, 2022

Study information

Verified date May 2022
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. It occurs when a bone marrow cell develops errors in its DNA. Certain tests are used to help detect the disease. But the results of these tests often disagree. Researchers want to review the results of tests of bone marrow and cerebrospinal fluid (CSF) from people with ALL. They want to try to find the best ways to detect the disease. Objective: To compare results of certain bone marrow and CSF tests for detecting ALL, in order to see how much and how often the results disagreed. Eligibility: Children and young adults with ALL or lymphoblastic lymphoma who were enrolled in certain previous studies and consented for their data to be used. Design: Investigators will review participants medical records. They will collect data like the participant s gender, age, and when their tests were done. They will also collect results from tests like: Bone marrow tests Flow cytometry tests Imaging CSF cell count All of the stored data will be labeled by a code that only the study team at the research site can link to the participant. Data will be stored in password protected computers. ...


Description:

Minimal residual disease detection in the bone marrow is highly prognostic for disease relapse in patients with acute lymphoblastic leukemia (ALL) and is determined based on a single bone marrow aspirate sample. Our anecdotal experience over the past decade in the Pediatric Oncology Branch (POB) has led us to believe that a bone marrow aspirate as the only metric for disease detection may not be adequate, but a systematic review detailing our experience and reporting on instances where we have identified discrepancies in disease status has not been performed to confirm our hypothesis. Additionally, patients with ALL also may have CNS involvement by disease. Current standard of care assessment of disease in the central nervous system (CNS) consists of cerebrospinal (CSF) fluid sampling and evaluation for blasts by cytology only, which may not identify occult levels of CNS disease. Flow cytometry-based CSF testing is highly dependent on the media used for CNS specimens and the expertise of the center performing these studies. NCI Flow cytometry has established expertise in CNS disease evaluation. In evaluation of patients with ALL for POB treatment protocols, we have observed cases where there is a discrepancy between cytopathology and flow cytometry results. Recent literature in ALL indicates that subclinical CNS disease may be relevant to patient outcomes. With a primary goal of identifying the optimal methods for disease detection in ALL, this protocol is a retrospective chart review of bone marrow evaluations and cerebrospinal fluid results in patients with ALL or lymphoblastic lymphoma (LBL) who underwent treatment or evaluation in the Pediatric Oncology Branch of the National Cancer Institute. This study will not involve the use of specimens or participant contact. All data that is needed has already been collected and is available in CRIS records. Data will only be collected on patients with ALL or LBL where routine PET scans to follow EM disease, bone marrow and/or CSF evaluations were done as standard of care or on study and will largely be from trials where Dr. Nirali Shah is or has served as the PI (e.g., 12-C-0112, 15-C-0029.)


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date April 14, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 2 Years to 40 Years
Eligibility - INCLUSION CRITERIA: Subjects with ALL or LBL enrolled in any of the source protocols: -98-C-0037, 08-C-0123, 10-C-0220, 11-C-0073, 12-C-0112, 14-C-0175, 15-C-0029, 18-C-0059 EXCLUSION CRITERIA: Patients who opted out of storage of specimens/data for future use on prior studies will be excluded from this study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Cancer Institute (NCI) Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To identify the frequency and degree of disease discrepancies in identification of bone marrow involvement by ALL when comparing bone marrow biopsy to bone marrow aspirate to flow cytometric disease detection. To identify the frequency and degree of disease discrepancies in identification of bone marrow involvement by ALL when comparing bone marrow biopsy to bone marrow aspirate to flow cytometric disease detection. 1 year
Primary To identify the frequency of discrepancies in identification of CNS involvement by leukemia when comparing flow cytometry to cytopathology. To identify the frequency of discrepancies in identification of CNS involvement by leukemia when comparing flow cytometry to cytopathology. 1 year
Primary To identify and characterize immunophenotypic changes in leukemic cells over time and in response to targeted therapy. To identify and characterize immunophenotypic changes in leukemic cells over time and in response to targeted therapy. 1 year
Primary To comprehensively characterize EM disease including incidence, presentation, risk factors for and radiographic presentation of disease. To comprehensively characterize EM disease including incidence, presentation, risk factors for and radiographic presentation of disease. 1 year
See also
  Status Clinical Trial Phase
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Completed NCT00458250 - Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H Phase 1
Completed NCT02264873 - Phase I, Dose Escalation Study of Decitabine Phase 1
Recruiting NCT01015742 - Unrelated Double Umbilical Cord Blood Units Transplantation Phase 2/Phase 3
Completed NCT00475280 - "Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients Phase 2
Recruiting NCT03331211 - Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia N/A
Terminated NCT01100658 - Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors N/A
Completed NCT00241358 - Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies Phase 1/Phase 2
Completed NCT01976442 - Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia N/A
Recruiting NCT00619879 - Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Phase 3
Completed NCT00179764 - Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) N/A
Terminated NCT01045382 - MSC and HSC Coinfusion in Mismatched Minitransplants Phase 2
Completed NCT00186901 - A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors Phase 3
Completed NCT00859586 - Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation N/A
Terminated NCT00539656 - Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers Phase 1/Phase 2
Terminated NCT01186328 - EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Phase 1
Terminated NCT01158885 - Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia Phase 2
Completed NCT02888990 - Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT03235973 - Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes Phase 1